The London Company, an investment management company, released “The London Company SMID Cap Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S. equities traded higher during the fourth quarter, with most of the major indices posting positive gains. Economic data released during the quarter was positive, though somewhat inconsistent. The portfolio returned 1.9% (1.7%, net) in the quarter compared to a 0.6% increase for the Russell 2500 Index. Both stock selection and sector exposure led the portfolio to outperform in the quarter. For more information on the fund’s top picks in 2024, please check its top five holdings.
In its fourth quarter 2024 investor letter, The London Company SMID Cap Strategy emphasized stocks such as Bruker Corporation (NASDAQ:BRKR). Bruker Corporation (NASDAQ:BRKR) focuses on developing, manufacturing, and distributing scientific instruments, and analytical and diagnostic solutions. The one-month return of Bruker Corporation (NASDAQ:BRKR) was -9.12%, and its shares lost 39.08% of their value over the last 52 weeks. On February 25, 2025, Bruker Corporation (NASDAQ:BRKR) stock closed at $50.99 per share with a market capitalization of $7.73 billion.
The London Company SMID Cap Strategy stated the following regarding Bruker Corporation (NASDAQ:BRKR) in its Q4 2024 investor letter:
“Bruker Corporation (NASDAQ:BRKR) – BRKR shares lagged the broader market following a weaker than expected earnings report, where revenue missed consensus estimates and management cut guidance. The latter was attributable to the same culprits afflicting the broader life sciences tools space -China and biopharma. On a positive note, the CEO purchased shares on weakness, which helped boost sentiment. While we acknowledge the near-term uncertainty around the stock due to macro headwinds and recent acquisitions, we have conviction around the company’s favorable long-term prospects.”
A scientist in a laboratory wearing safety gear while operating a mass spectrometry machine.
Bruker Corporation (NASDAQ:BRKR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held Bruker Corporation (NASDAQ:BRKR) at the end of the fourth quarter compared to 31 in the third quarter. Bruker Corporation (NASDAQ:BRKR) reported revenues of $3.37 billion in the fiscal year 2024, representing a 13.6% increase compared to 2023. While we acknowledge the potential of Bruker Corporation (NASDAQ:BRKR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we discussed Bruker Corporation (NASDAQ:BRKR) and shared the list of best nanotechnology stocks to buy according to hedge funds. The London Company’s Large Cap Strategy added Bruker Corporation (NASDAQ:BRKR) to its portfolio during Q4 2024. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.